Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitriol + calcium is a combination therapy utilized as the conventional standard of care for the management of hypoparathyroidism, particularly in clinical research conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Calcitriol, the active form of vitamin D3 (1,25-dihydroxyvitamin D3), acts as an agonist at the vitamin D receptor (VDR) to enhance intestinal absorption of calcium and phosphorus. Supplemental calcium (often as calcium carbonate) provides the necessary elemental calcium to maintain serum levels in the absence of adequate parathyroid hormone (PTH). This regimen is used to prevent hypocalcemia and its associated symptoms, although it does not address the full physiological spectrum of PTH deficiency, such as impaired renal calcium reabsorption and phosphate excretion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitriol + calcium.